PolyPid Ltd. (PYPD) is advancing toward key regulatory milestones with its lead therapy D-PLEX100, supported by positive Phase 3 results and preparations for a 2026 New Drug Application submission.
Alongside regulatory progress, PolyPid is strengthening its financial position, engaging in partnership discussions, and reinforcing commercial readiness, making it a notable name to follow in the biopharma space.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.